40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors-Reference-Cited by-同舟云学术

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

Published:2013-07 Issue:7 Volume:11 Page:1260-1268
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Ljung R.¹,Karim F. A.²,Saxena K.³,Suzuki T.⁴,Arkhammar P.⁵,Rosholm A.⁶,Giangrande P.⁷,

Affiliation:

1. Department of Paediatrics and Malmö Centre for Thrombosis and Haemostasis; Lund University; Skåne University Hospital; Malmö Sweden

2. Haemophilia Centre; National Blood Centre; Kuala Lumpur Malaysia

3. Children's Hospital Boston; Harvard Medical School; Boston MA USA

4. Department of Laboratory Medicine; Tokyo Medical University; Tokyo Japan

5. Medical and Science; Haemophilia R&D Portfolio; Novo Nordisk A/S; Søborg Denmark

6. Biostatistics Biopharm; Novo Nordisk A/S; Søborg Denmark

7. Oxford Haemophilia and Thrombosis Centre; Churchill Hospital; Oxford UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.12237/fullpdf

Reference23 articles.

1. World Federation of Hemophilia Report on the Annual Global Survey 2010 World Federation of Hemophilia http://www1.wfh.org/publications/files/pdf-1427.pdf

2. Activity and regulation of glycoPEGylated factor VIIa analogs;Ghosh;J Thromb Haemost,2008

3. Effect of glycoPEGylation on factor VIIa binding and internalization;Sen;Haemophilia,2010

4. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives;Stennicke;Thromb Haemost,2008

5. The molar hydrodynamic volume changes of factor VIIa due to GlycoPEGylation;Plesner;J Pharm Biomed Anal,2011

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Site-directed mutagenesis of tissue factor pathway inhibitor–binding exosite D60A on factor VII results in a new factor VII variant with lower coagulant activity;Research and Practice in Thrombosis and Haemostasis;2024-01

2. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors;Expert Review of Hematology;2023-09-25

3. Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety;Research and Practice in Thrombosis and Haemostasis;2021-08

4. Sialyltransferase-mediated glycoPEGylation;Polymer-Protein Conjugates;2020

5. Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue;Blood Advances;2019-09-10